Organ (biology)

Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2023

Retrieved on: 
Tuesday, November 14, 2023
Independence, Research, NYSE, Telephone, Gynaecology, Freezing, Cleveland Clinic Akron General, Investment, Clinic, Traction, Patient, LUNA, FDA, Organ (biology), Intelligence, Machine learning, CIS, Mayo Clinic Hospital (Rochester), GAAP, Communication, RESEARCH, Growth, Commonwealth, Dentistry, Video game, Security (finance), Nursing, Cryptocurrency

We anticipate reaching important milestones in the upcoming quarters,” said Anthony Fernando, Asensus Surgical President and CEO.

Key Points: 
  • We anticipate reaching important milestones in the upcoming quarters,” said Anthony Fernando, Asensus Surgical President and CEO.
  • The LUNA System's development is in progress and is now entering the testing and evaluation phase before regulatory submissions.
  • Future milestones include freezing the system's design in early 2024, followed by verification and validation testing, and pilot manufacturing.
  • Revenue in the third quarter of 2023 included $0.5 million in lease revenue, $0.3 million in instruments and accessories, and $0.3 million in services.

67% Say the Economy Will Improve or Stay the Same, According to the EAA 2024 National Business Trends Survey

Retrieved on: 
Thursday, November 16, 2023
Acquisition, Organization, Investment, Artificial intelligence, Recruitment, Marketing, Movement, EAA, Organ (biology), Executive, Clothing, Management, Nursing

MILWAUKEE, Nov. 16, 2023 /PRNewswire-PRWeb/ -- The 2024 National Business Trends Survey from the Employer Associations of America (EAA) shows business leaders are feeling the most confident in the economy in recent years. Sixty-seven percent of organizations say the economy will improve or stay the same, compared with 49% for the 2023 report.

Key Points: 
  • MILWAUKEE, Nov. 16, 2023 /PRNewswire-PRWeb/ -- The 2024 National Business Trends Survey from the Employer Associations of America (EAA) shows business leaders are feeling the most confident in the economy in recent years.
  • Sixty-seven percent of organizations say the economy will improve or stay the same, compared with 49% for the 2023 report.
  • According to the 2024 EAA National Business Trends Survey, 72% of executives also project flat to slight increases in sales/revenue for the upcoming year, as compared to 53% in 2023.
  • The top five responses in the 2024 survey were:
    Inflation was once again taken into consideration in the current survey.

Asensus Surgical Announces Klinikum Idar-Oberstein Hospital in Germany to Initiate Senhance Surgery Program

Retrieved on: 
Monday, November 6, 2023
NYSE, RESEARCH, Health, Organ (biology), Intelligence, PARK, Deep learning, Hospital, Dentistry

"We are pleased to collaborate with Klinikum Idar-Oberstein Hospital as they aim to enhance patient outcomes through advanced minimally invasive surgery.

Key Points: 
  • "We are pleased to collaborate with Klinikum Idar-Oberstein Hospital as they aim to enhance patient outcomes through advanced minimally invasive surgery.
  • The innovative features of the Senhance System, combined with the established laparoscopic approach, will bring valuable enhancements to the Idar-Oberstein Hospital," commented Anthony Fernando, President and CEO of Asensus Surgical.
  • "We look forward to working with Dr. Christos Zigouris and team to ensure the success of their team’s Senhance program."
  • “With the introduction of the Senhance program at Idar-Oberstein Hospital, we are raising the bar for patient care,” said Dr. med.

Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer

Retrieved on: 
Tuesday, September 12, 2023
Oxidative phosphorylation, Pancreatic cancer, NF, University, Cell death, GAPDH, Glomus tumor, ATP, Enzyme, Agonal respiration, Quality of life, Cancer, Research, Ruhr University Bochum, Molecular medicine, University of Duisburg-Essen, Patient, Manuscript, Apoptosis, Organ (biology), Journal of Cellular and Molecular Medicine, ST, Factorization of polynomials, Pharmaceutical industry, Panaveli

BERWYN, PA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for patients, today announced publication of positive data in the peer-reviewed Journal of Cellular and Molecular Medicine in a manuscript titled, “GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells1.” The publication by Majchrzak-Stiller, et al. (2023) details the multiple sites of action of GP-2250 in the disruption of energy production of cancer cells and the downregulation of tumor promoting transcription factors.

Key Points: 
  • GP-2250 is a highly selective yet broadly active cancer therapeutic with a unique mechanism of action that suppresses cancer by disrupting its energy metabolism, leading to cancer cell death through several validated mechanisms.
  • GP-2250 is currently being studied in a Phase 1 clinical trial for pancreatic cancer.
  • Results of the preclinical study showed that at the lowest dose of GP-2250 tested (250 μM), a significant decrease in ATP was apparent at 6 hours in both pancreatic cancer cell lines.
  • We are pleased with the results GP-2250 demonstrated, and the metabolic and transcriptional findings provide molecular targets for GP-2250.

Microphysiological Systems Conference 2023: A Deep Dive into Technologies & Applications - Innovations in 3D-Culture, Organoids, and Organs-on-Chips fields (Orlando, Florida - July 26-27, 2023)

Retrieved on: 
Tuesday, July 4, 2023
Central Florida, City University of Hong Kong, La Jolla Institute for Immunology, University, Impact, Engineering, Organoid, Associate professor, University of Florida, Electrical engineering, AME Publishing Company, MPS, Organ (biology), Royal Army Medical Corps, Novo Nordisk, University of Central Florida, Integration, Cornell University, Conference, City University, 3D printing, Management, Medical imaging, Chemistry

DUBLIN, July 3, 2023 /PRNewswire/ -- The "Microphysiological Systems 2023: A Deep Dive into Technologies & Applications" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 3, 2023 /PRNewswire/ -- The "Microphysiological Systems 2023: A Deep Dive into Technologies & Applications" conference has been added to ResearchAndMarkets.com's offering.
  • Topics to be covered include 3D-cell based screening methods, high content screening, and analysis, the use of model systems, and novel approaches for physiologically-relevant analysis of cell systems as well as building these systems (MPS systems).
  • The host is honored that Professor Mike Shuler, Samuel B. Eckert Professor of Engineering at Cornell University and President of Hesperos will be Chairperson of this Conference.
  • Conference Attendees Receive Full Access to the Co-Located EV Conference for Maximal Networking and Scientific Exchange.

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)

Retrieved on: 
Thursday, June 29, 2023
Survival rate, STAT3, University, Glomus tumor, Bromodeoxyuridine, Merkel cell polyomavirus, Necrosis, Journal of Cancer Research and Clinical Oncology, Skin cancer, Quality of life, Ruhr University Bochum, University of Duisburg-Essen, AKT, Patient, Manuscript, Cancer, Flow cytometry, MCC, Apoptosis, MTT, Organ (biology), ST, Pharmaceutical industry, Vaccine, Panaveli, Angela Merkel, Erosion (morphology)

BERWYN, Pa., June 29, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them, today announced the publication of positive preliminary data in a manuscript titled, “The effect of GP‑2250 on cultured virus‑negative Merkel cell carcinoma cells: preliminary results1,” in the peer-reviewed Journal of Cancer Research and Clinical Oncology.

Key Points: 
  • The objective of the preclinical study was to investigate the effects of GP-2250 on Merkel cell polyomavirus (MCPyV)-negative MCC cells.
  • Greg Bosch, Chairman and CEO of Panavance Therapeutics commented, “We are encouraged by these preclinical findings in this rare, aggressive form of skin cancer.
  • This study was able to show that GP-2250 has significant, dose-dependent cytotoxic effects on MCC cells as well as reduced cancer cell proliferation and migration.
  • GP-2250’s effects on cell viability, proliferation and migration were evaluated by means of MTT, BrdU, and scratch assays, respectively.

Microphysiological Systems Conference 2023: A Deep Dive into Technologies & Applications - Innovations in 3D-Culture, Organoids, and Organs-on-Chips fields (Orlando, Florida - July 26-27, 2023) - ResearchAndMarkets.com

Retrieved on: 
Monday, June 19, 2023
Health, Biotechnology, Central Florida, City University of Hong Kong, La Jolla Institute for Immunology, University, Impact, Engineering, Organoid, Associate professor, University of Florida, Electrical engineering, AME Publishing Company, MPS, Organ (biology), Royal Army Medical Corps, Novo Nordisk, University of Central Florida, Integration, Cornell University, Conference, City University, 3D printing, Management, Medical imaging, Chemistry

The "Microphysiological Systems 2023: A Deep Dive into Technologies & Applications" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microphysiological Systems 2023: A Deep Dive into Technologies & Applications" conference has been added to ResearchAndMarkets.com's offering.
  • The host is honored that Professor Mike Shuler, Samuel B. Eckert Professor of Engineering at Cornell University and President of Hesperos will be Chairperson of this Conference.
  • Conference Attendees Receive Full Access to the Co-Located EV Conference for Maximal Networking and Scientific Exchange.
  • **The Conference Features Scientific Presentations from Academics, Technical Presentations from Industry, Technology Spotlight Presentations from Technology-Tools Vendors, and an Exhibit Hall with Companies Showcasing their Commercial Offerings.

EQS-News: Digital health start-up Capreolos GmbH launches Ready4OP app to support patients before major surgical procedures

Retrieved on: 
Thursday, June 15, 2023
Clinic, Cancer, Breast, Thorax, Practitioner, Patient, Physician, Hernia, Abdomen, Knowledge, Diagnosis, Textbook, Health, Health literacy, Organ (biology), Nursing

The Ready4OP app also provides a guide to questions for doctor-patient discussions.

Key Points: 
  • The Ready4OP app also provides a guide to questions for doctor-patient discussions.
  • It is intended to help patients and their care givers to optimally prepare for the first consultation with their surgeon.
  • the best possible preparation for major operations.”
    Dr. Dora Zmuc, Chief Business Development Officer at Capreolos and originator of the idea behind the Ready4OP app, explained: “The Ready4OP app is our first product in a still young market.
  • The Ready4OP app is the first step taken by Capreolos GmbH to build a comprehensive prehabilitation program.”
    The Ready4OP app is available free of charge in the Apple Appstore and in the Google Playstore.

Digital health start-up Capreolos GmbH launches Ready4OP app to support patients before major surgical procedures

Retrieved on: 
Thursday, June 15, 2023
Clinic, Cancer, Breast, Thorax, BAD, Practitioner, Patient, Physician, Hernia, Abdomen, Knowledge, Diagnosis, Textbook, Health, Health literacy, Organ (biology), Nursing

The Ready4OP app also provides a guide to questions for doctor-patient discussions.

Key Points: 
  • The Ready4OP app also provides a guide to questions for doctor-patient discussions.
  • It is intended to help patients and their care givers to optimally prepare for the first consultation with their surgeon.
  • the best possible preparation for major operations.”
    Dr. Dora Zmuc, Chief Business Development Officer at Capreolos and originator of the idea behind the Ready4OP app, explained: “The Ready4OP app is our first product in a still young market.
  • The Ready4OP app is the first step taken by Capreolos GmbH to build a comprehensive prehabilitation program.”
    The Ready4OP app is available free of charge in the Apple Appstore and in the Google Playstore.